LIVTENCITY Drug Patent Profile

Which patents cover Livtencity, and what generic alternatives are available?

Livtencity is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in seventeen countries.

The generic ingredient in LIVTENCITY is maribavir. One supplier is listed for this compound. Additional details are available on the maribavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Livtencity

Livtencity was eligible for patent challenges on November 23, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 23, 2028. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for LIVTENCITY

International Patents:	32
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Patent Applications:	835
Drug Prices:	Drug price information for LIVTENCITY
What excipients (inactive ingredients) are in LIVTENCITY?	LIVTENCITY excipients list
DailyMed Link:	LIVTENCITY at DailyMed

See drug prices for LIVTENCITY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LIVTENCITY

Constraining patent/regulatory exclusivity:

FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG) WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT (WITH OR WITHOUT GENOTYPIC RESISTANCE) WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET

NDA:

215596

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LIVTENCITY

Drug Class	Cytomegalovirus pUL97 Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Cytomegalovirus pUL97 Kinase Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for LIVTENCITY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIVTENCITY	Tablets	maribavir	200 mg	215596	3	2025-11-24

US Patents and Regulatory Information for LIVTENCITY

LIVTENCITY is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG) WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT (WITH OR WITHOUT GENOTYPIC RESISTANCE) WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes	12,447,170
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes	12,433,907
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes	12,447,169

EU/EMA Drug Approvals for LIVTENCITY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch	Livtencity	maribavir	EMEA/H/C/005787LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).Consideration should be given to official guidance on the appropriate use of antiviral agents.	Authorised	no	no	yes	2022-11-09

International Patents for LIVTENCITY

See the table below for patents covering LIVTENCITY around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	202339770	Use of MARIBAVIR in treatment regimens
Israel	312428	שימוש במאריבאביר לטיפול ולשיטות טיפול שלהן (Use of maribavir for the treatment of and treatment regimens thereof)
China	119751518	制备马立巴韦的方法 (Process for preparation of Maripasvir)
Argentina	130743
European Patent Office	4480956	INHIBITEURS VIRAUX, LEUR SYNTHÈSE ET LEURS INTERMÉDIAIRES (VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO)

Market Dynamics and Financial Trajectory of LIVTENCITY

Last updated: February 19, 2026

LIVTENCITY (maribavir) is an antiviral drug approved for treating cytomegalovirus (CMV) infections in transplant patients. Its market potential is influenced by factors including clinical efficacy, competing therapies, patent status, and market adoption pace.

Current Market Position

LIVTENCITY received U.S. FDA approval in November 2021 for CMV infections post-transplantation. It is marketed by Takeda Pharmaceutical. The drug faces competition primarily from existing CMV treatments such as ganciclovir, valganciclovir, cidofovir, and foscarnet, which have long-standing market presence.

Clinical Profile and Advantages

• Mechanism: Inhibits CMV-specific kinase UL97.
• Efficacy: Demonstrates superior activity against resistant strains.
• Safety: Shows a more favorable safety profile compared to ganciclovir and its derivatives.

This clinical profile positions LIVTENCITY as an alternative for resistant CMV, potentially increasing market share over time.

Market Size and Growth Drivers

Target Population

• Transplant patients: Approximately 45,000 kidney, liver, lung, and heart transplants annually in the U.S. (approx. 15,000 with high-risk CMV).
• CMV infections: CMV reactivation occurs in 30-70% of transplant recipients, with active disease requiring treatment.

Market value estimates

• U.S. market: Estimated at $300 million in 2023.
• Global market: Projected to reach $1.2 billion by 2030 due to increasing transplant procedures and resistance issues.

Growth factors

• Rising transplant rates worldwide.
• Emerging resistance to existing antiviral therapies.
• Approval extending to pediatric and other transplant categories (pending regulatory considerations).

Competitive Landscape

Therapy	Approval Year	Market Share (Estimated, 2023)	Key Attributes
Ganciclovir	1980s	60%	Established, low cost, resistance issues
Valganciclovir	2001	20-25%	Oral formulation, routine use
Cidofovir	1980s	5%	Used for resistant cases, nephrotoxicity risk
Foscarnet	1987	5%	Alternative for resistant strains
LIVTENCITY	2021	5% (initial)	Resistance efficacy, better safety profile

Market penetration of LIVTENCITY is limited initially but expected to grow as resistance issues expand.

Financial Trajectory

Revenue forecasts

• 2023: Approximately $50 million globally.
• 2025: Expected to reach $150-200 million as adoption increases.
• 2030: Potentially over $600 million, assuming growth in resistant CMV treatments and expanded indications.

Pricing strategy

• Estimated wholesale acquisition cost (WAC) around $55,000-$75,000 per treatment course.
• Cost competitiveness challenged by existing generics, but clinical advantages support premium pricing in resistant cases.

Revenue growth assumptions

• Market share growth from 5% in 2023 to 20-25% in 2030 within the transplant CMV segment.
• Increased adoption driven by clinical validation and expanded indication approvals.

Market Challenges and Opportunities

Challenges:

• Competitive pressure from generic therapies.
• Slow adoption due to cautious prescriber preferences and safety profiling.
• Reimbursement policies vary across regions, affecting access.

Opportunities:

• Expansion into pediatric patients and broader transplant categories.
• Developing partnership agreements with healthcare providers and payers.
• Potential for combination therapies targeting resistant CMV strains.

Regulatory and Patent Status

• Patent portfolio extends to 2035, limiting generic entry until then.
• Regulatory pathways for additional indications are being explored, which could extend LIVTENCITY's market life.

Conclusion

LIVTENCITY's market trajectory is characterized by limited initial adoption due to competition and cost but is poised for growth as resistance becomes a larger concern with the expanding transplant population. Financial gains depend on clinical validation, regulatory support, and strategic positioning.

---

Key Takeaways

• LIVTENCITY entered a crowded market with established therapies but offers advantages in resistant CMV cases.
• U.S. revenue is approximately $50 million (2023), with global growth prospectively accelerating towards $600 million by 2030.
• Market penetration depends on resistance management, regulatory expansions, and payer coverage.
• Patent protection extends until 2035, offering a window for sustained sales.
• Future growth hinges on broader indications, pediatric approvals, and market acceptance.

---

FAQs

1. When did LIVTENCITY receive FDA approval?
November 2021.

2. What is LIVTENCITY’s primary clinical advantage?
Superior activity against resistant CMV strains with a better safety profile compared to traditional therapies.

3. What is the main market challenge?
Existing generic antivirals and cautious prescriber adoption limit immediate market share growth.

4. Are there plans for expanding LIVTENCITY indications?
Yes, clinical trials are ongoing for pediatric use and other transplant categories.

5. What is the anticipated global market size for LIVTENCITY by 2030?
Approximately $1.2 billion, driven by increasing transplant procedures and resistance issues.

---

References

[1] U.S. Food and Drug Administration (FDA). (2021). LIVTENCITY (maribavir) approval letter.
[2] IQVIA. (2023). U.S. Transplant Patient Market Data.
[3] MarketWatch. (2023). Global antiviral market forecast.
[4] Takeda Pharmaceutical. (2022). LIVTENCITY prescribing information.